Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Olomoucine 是 Cdk2/cyclin A、Cdc2/CyclinB、CDK2/CyclinE、CDK5/p35 和 ERK1/p44 MAP 激酶的 ATP 竞争性抑制剂,IC50 分别为 7、7、7、3 和 25 µM。 Olomoucine 调节细胞周期并表现出抗黑色素肿瘤活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 687 | 现货 | ||
5 mg | ¥ 1,620 | 现货 | ||
10 mg | ¥ 2,610 | 现货 | ||
25 mg | ¥ 4,390 | 现货 | ||
50 mg | ¥ 6,260 | 现货 | ||
100 mg | ¥ 8,590 | 现货 | ||
500 mg | ¥ 17,200 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,550 | 现货 |
产品描述 | Olomoucine is an ATP competitive inhibitor of Cdk2/cyclin A, Cdc2/CyclinB, CDK2/CyclinE, CDK5/p35, and ERK1/p44 MAP kinase with IC50s of 7, 7, 7, 3 and 25 µM, respectively. Olomoucine regulates cell cycle and exhibits anti-melanin tumor activities. |
体外活性 | In Rdditapes oocytes, Olomoucine (0-150 μM) inhibits prophase/metaphase transition. In CTLL-2 cells, Olomoucine (0-1000 μM) inhibits DNA synthesis and triggers a Gl arrest similar to interleukin-2 deprivation. In NSCLC MB65 cells, Olomoucine (0-100 μM) inhibits Gl/S transition[1]. Olomoucine inhibits tumor cell survival with IC50s of 32.35, 42.15, and 82.30 μM for dog, mouse B16, and human melanoma, respectively[4]. |
体内活性 | In female Balb C− mice, Olomoucine results faster plasma concentration decreasing with 50 mg/kg (as single agent) than 16.6 mg/kg (as cassette)[3]. In dog with spontaneous melanoma, Olomoucine (8 mg/kg; i.v.) induces programmed cell death of cancer cells and results in rapid eradication of at least 68% of the tumor cells without side effects[4]. |
分子量 | 298.34 |
分子式 | C15H18N6O |
CAS No. | 101622-51-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 95 mg/mL (318.43 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.3519 mL | 16.7594 mL | 33.5188 mL | 83.797 mL |
5 mM | 0.6704 mL | 3.3519 mL | 6.7038 mL | 16.7594 mL | |
10 mM | 0.3352 mL | 1.6759 mL | 3.3519 mL | 8.3797 mL | |
20 mM | 0.1676 mL | 0.838 mL | 1.6759 mL | 4.1899 mL | |
50 mM | 0.067 mL | 0.3352 mL | 0.6704 mL | 1.6759 mL | |
100 mM | 0.0335 mL | 0.1676 mL | 0.3352 mL | 0.838 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Olomoucine 101622-51-9 Cell Cycle/Checkpoint MAPK ERK CDK Inhibitor cyclindependent kinases cdc2 purines cell cycle non-small cell lung cancer cell line MR6.5 protein kinases Cyclin dependent kinase xenopus laevis oocytes proliferation inhibit cdk2 inhibitor